- Home
- LNKB vs LRMR Comparison
LNKB vs LRMR Comparison
Compare LNKB & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNKB | LRMR |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.0M | 280.0M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LNKB | LRMR |
|---|---|---|
| Price | $8.48 | $5.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $16.29 |
| AVG Volume (30 Days) | 134.5K | ★ 6.3M |
| Earning Date | 04-27-2026 | 04-14-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ 205.97 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $167,586,000.00 | N/A |
| Revenue This Year | $10.18 | N/A |
| Revenue Next Year | $9.33 | N/A |
| P/E Ratio | $10.46 | ★ N/A |
| Revenue Growth | ★ 152.83 | N/A |
| 52 Week Low | $6.09 | $1.61 |
| 52 Week High | $9.59 | $6.42 |
Technical Indicators
Market Signals| Indicator | LNKB | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 40.14 | 63.82 |
| Support Level | $8.44 | $3.18 |
| Resistance Level | $9.02 | $5.37 |
| Average True Range (ATR) | 0.27 | 0.52 |
| MACD | -0.08 | 0.16 |
| Stochastic Oscillator | 16.15 | 66.13 |
Price Performance
Historical ComparisonAbout LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.